07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

Gynevac: Phase III started

AmVac began a double-blind, placebo-controlled, Hungarian Phase III trial to evaluate intramuscular Gynevac in 240 patients. AmVac said a previous version of Gynevac containing thiomersal -- a mercury-containing organic preservative -- is approved in Hungary...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Company News

AmVac infectious news

AmVac received two five-year grants to develop vaccines under the EU's Framework Programme 7 (FP7). The projects are part of initiatives that include other companies and research institutes. The first program received about €6 million...
07:00 , Jun 25, 2009 |  BC Innovations  |  Strategy

Science for export

Although every major university or institute would like to be located in a biotech hub and keep its discoveries close to home, only a few true hubs exist. For everyone else, the question is whether...
08:00 , Mar 2, 2009 |  BC Week In Review  |  Company News

Mbiotec, Helmholtz Center for Infection Research deal

MBiotec received exclusive, worldwide rights to develop and commercialize the center's MALP-2S and its derivatives to treat cancer. The synthetic analog of MALP-2, a lipopeptide from Mycoplasma fermentas has completed a Phase I/II trial to...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Company News

AmVac, National Health Research Institutes deal

The partners will use AmVac's MALP-2 synthetic lipopeptide vaccine adjuvant to develop an intranasal avian influenza vaccine, to which they will share rights. Phase I trials are planned for 2011. Further terms were not disclosed....
07:00 , Jun 16, 2008 |  BC Week In Review  |  Company News

AmVac, Bayer deal

AmVac and Bayer’s Bayer Innovation GmbH subsidiary partnered to research and develop an influenza vaccine using antigens that Bayer’s Icon Genetics GmbH subsidiary will produce in tobacco plants. The vaccine will use AmVac’s MALP-2, a...
01:20 , Jun 13, 2008 |  BC Extra  |  Company News

AmVac, Bayer to develop influenza vaccine

AmVac (Zug, Switzerland) and Bayer (Xetra:BAY) partnered to research and develop an influenza vaccine using antigens that Bayer's Icon Genetics GmbH subsidiary will produce in tobacco plants. The vaccine will use AmVac's MALP-2, a synthetic...
08:00 , Jan 7, 2008 |  BC Week In Review  |  Company News

AmVac management update

AmVac AG , Zug, Switzerland   Business: Infectious, Genitourinary   Hired: Wolfgang Schmidt as COO  ...
08:00 , Dec 17, 2007 |  BC Week In Review  |  Company News

AmVac, Ascension GmbH, Helmholtz Center for Infection Research, Max Planck Society deal

AmVac received an exclusive, worldwide license to develop and commercialize vaccines using a modified non-replicating Sendai virus from Max Planck Innovation GmbH, the society's technology transfer agency. Max Planck Innovation will receive an upfront payment...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Company News

AmVac management update

AmVac AG , Zug, Switzerland   Business: Infectious, Genitourinary   Hired: Michel Klein as CSO, formerly VP of science and technology at sanofi-aventis Group 's Aventis Pasteur division  ...